The two approved TPO-RAs, eltrombopag [13, 29, 30] and romiplostim [31], have achieved good results [29, 31, 32] and are recommended as second-line therapeutic options [16, 17] for adult ITP patients. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.